NYSE:ABT
Abbott Labs (ABT)
Financials 
Technical Analysis 
Sep 12, 2026, 12:00 amThis summary was created by AI, based on 13 opinions in the last 12 months.
Abbott Labs (ABT) has faced significant challenges over the past year, marked by declining stock performance and reduced growth expectations. While its recent acquisition aimed at expanding its cancer treatment portfolio is viewed positively, it is anticipated to take time before it becomes accretive to earnings. Analysts note that although growth has slowed and market share has been lost, the company's diagnostics and devices business shows signs of potential recovery. Despite these hurdles, many experts still consider ABT a high-quality name in the healthcare sector, highlighting its reasonable valuation compared to historic PE ratios and consistent dividend history. Overall, while caution is advised due to technical weaknesses and elevated competition, there remains an underlying belief in the stock's long-term viability.
Has owned this many years. She likes healthcare because of aging demographics. They made a lot of cash during Covid and have used that cash for M&A and R&D. Pays a nice 2.5% dividend. Has an established track record of raising their dividend annually. Trades at a reasonable PE. Lags healthcare, but still likes ABT.
Christine Poole
It is a diversified medical device company with a large diagnostic business. It has made several acquisitions giving it a very diversified platform and is executing well in the cardio-vascular and diabetes fields. Buy 20 Hold 7 Sell 1
Paul MacDonald
Defensive. Very strong growth platform. Diagnostic business is right-sizing now, but organic growth of other businesses is double digits. Valuation is a bit more expensive at 23x earnings, but free cashflow yield is about 4%.
Instead of innovation, they tend to acquire and enhance, which has been a knock against them. Big wins in cardiac portfolio and FreeStyle Libre glucose monitoring. Businesses are right in the sweet spot. Yield is 1.83%.
Chris BlumasThey made the Covid testing kits which generated $20 billion in revenues, so shares got ahead of itself. The market has ignored any such companies since then, but these earnings will eventually work their way up again. ABT has given guidance ex-Covid tests, meaning double-digit organic growth. This is a long-time core holding. They're in medtech and medical procedures are ramping up (a tailwind). Pays a constant and long-growing dividend now around 2.5%. She likes healthcare as a play on the aging population.
Christine PooleStill owns shares in the company.
Believes healthcare a good defensive name.
Target price of $110 per share.
Good performance in the past for the portfolio.
Averaged 16% growth the past 5 years.
Good company for the long term investor.
Brianne Gardner
Brianne GardnerChristine Poole
Stockchase Discover
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
It is a diversified global health care company with four operating divisions. Sales dropped dramatically after benefiting during Covid but the basic business is doing well with all divisions growing organically. Weight loss patients are using their drugs to monitor glucose. It has had 51 years of dividend increases. Buy 19 Hold 7 Sell 0
(Analysts’ price target is $116.88)